Tower Research Capital (TRC)’s Dimension Therapeutics, Inc DMTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio DMTX Stock Details DMTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-10,035	Closed	-$14K	–	4493
2017 Q2	$14K	Sell	10,035 -11,638	-54%	-$15.8K	﹤0.01%	1444
2017 Q1	$38K	Buy	21,673 +21,391	+7,585%	+$56.7K	﹤0.01%	888
2016 Q4	$1K	Sell	282 -342	-55%	-$1.82K	﹤0.01%	3761
2016 Q3	$5K	Buy	624 +474	+316%	+$3.43K	﹤0.01%	2634
2016 Q2	$1K	Buy	+150	New	+$1.14K	﹤0.01%	4361
2016 Q1	–	Sell	-1,273	Closed	-$14K	–	5803
2015 Q4	$14K	Buy	+1,273	New	+$16.1K	﹤0.01%	1762

Other funds holding DMTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HIM

HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Tower Research Capital (TRC)'s DMTX Position: Q3 2017 in Review

Tower Research Capital (TRC) sold out of Dimension Therapeutics, Inc (DMTX) in Q3 2017, closing a stake of 10,035 shares — an estimated $14K sold.

Tower Research Capital (TRC) first reported a position in DMTX in Q4 2015 and held it in 6 quarters. The position peaked at $38K in Q1 2017. 34 funds tracked by Wall St. Rank hold DMTX as of Q3 2017.

Tower Research Capital (TRC) reported no remaining Dimension Therapeutics, Inc position as of Q3 2017 after selling out during the quarter.
Tower Research Capital (TRC) sold 10,035 Dimension Therapeutics, Inc shares in Q3 2017, an estimated $14K.
Tower Research Capital (TRC) first reported a position in Dimension Therapeutics, Inc in Q4 2015 and held it in 6 quarters.
Tower Research Capital (TRC)'s Dimension Therapeutics, Inc position peaked at $38K in Q1 2017.
34 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q3 2017.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2017, filed 14 Nov 2017.